Cystatin C and beta-2-microglobulin (B2M) are filtration markers associated with adverse outcomes in nontransplant populations, sometimes with stronger associations than for creatinine. We evaluated associations of estimated glomerular filtration rate from cystatin C (eGFR cys ), B2M (eGFR B2M ), and creatinine (eGFR cr ) with cardiovascular outcomes, mortality, and kidney failure in stable kidney transplant recipients using a case-cohort study nested within the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. A random subcohort was selected (N = 508; mean age 51.6 years, median transplant vintage 4 years, 38% women, 23.6% nonwhite race) with enrichment for cardiovascular events (N = 306; 54 within the subcohort), mortality (N = 208; 68 within the subcohort), and kidney failure (N = 208; 52 within the subcohort). Mean eGFR cr , eGFR cys , and eGFR B2M were 46.0, 43.8, and 48.8 mL/min/1.73m 2 , respectively. After multivariable adjustment, hazard ratios for eGFR cys and eGFR B2M <30 versus 60+ were 2.02 (95% confidence interval [CI] 1.09-3.76; p = 0.03) and 2.56 (1.35-4.88; p = 0.004) for cardiovascular events; 3.92 (2.11-7.31) and 4.09 (2.21-7.54; both p < 0.001) for mortality; and 9.49 (4.28-21.00) and 15.53 (6.99-34.51; both p < 0.001) for kidney failure. Associations persisted with additional adjustment for baseline eGFR cr . We conclude that cystatin C and B2M are strongly associated with cardiovascular events, mortality, and kidney failure in stable kidney transplant recipients.
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Introduction
Kidney transplant recipients have increased risk of cardiovascular disease, kidney failure, and all-cause mortality. Lower levels of kidney function, ascertained with serum creatinine or glomerular filtration rate (GFR) estimated from serum creatinine (eGFR cr ) is independently associated with cardiovascular and kidney disease outcomes in a wide range of nontransplant populations (1) (2) (3) (4) , and is associated with increased risk of cardiovascular events (5) (6) (7) (8) (9) , all-cause mortality (10) , and graft loss (11) (12) (13) in kidney transplant recipients.
Cystatin C and beta-2 microglobulin (B2M) are lowmolecular-weight serum proteins that are being investigated as novel filtration markers. In nontransplant populations, these filtration markers and their related GFR estimates (eGFR cys , eGFR B2M ) are independent predictors of mortality, cardiovascular events, and end-stage renal disease, and in some cases show stronger risk associations than those observed for serum creatinine and eGFR cr (14) (15) (16) (17) (18) (19) (20) (21) . It is hypothesized that such differences in risk associations among filtration markers reflect differences in factors other than GFR that influence their serum levels. The non-GFR determinants of filtration markers may differ in kidney transplant recipients compared to the nontransplant population, leading to differences in risk associations between these populations. Few studies have evaluated risk associated with low-molecular-weight serum protein levels in kidney transplant recipients. Prior work suggests that higher B2M is associated with greater eGFR decline 1-2 years posttransplant (22) and that both higher cystatin C and B2M are associated with increased risk of mortality (23) and graft loss (23) (24) (25) in transplant recipients. It is not known, however, whether the potential advantage of the lowmolecular-weight serum protein filtration markers over creatinine for estimating cardiovascular and kidney disease risk associations that have been observed in the nontransplant population are present among transplant patients. If the cystatin C and B2M are shown to be strong markers of major clinical outcomes in transplant recipients, they may prove useful in risk prediction and risk stratification in this population.
We have previously demonstrated an independent association of baseline eGFR cr with cardiovascular disease and all-cause mortality in a post-hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial (8) . The aim of the current study is to evaluate risk associations of eGFR cys and eGFR B2M with cardiovascular outcomes, all-cause mortality, and kidney failure in stable kidney transplant recipients in a casecohort study drawn from the FAVORIT Trial, and whether these associations are independent of eGFR cr .
Materials and Methods

Study population
Our study sample was drawn from the FAVORIT Trial (clinicaltrials.gov: NCT00064753), a multicenter, double-blind, randomized clinical trial conducted to determine whether lowering homocysteine levels with vitamin therapy reduced the rate of cardiovascular outcomes (26, 27) . The For the present analysis, we utilized an established case-cohort study nested within the FAVORIT Trial. The case-cohort study is an efficient design to evaluate novel factors associated with multiple outcomes with a study sample. It includes (1) a random sample of participants drawn from the overall original study (the "subcohort") that is additionally enriched to include (2) all outcomes of interest that occur within the overall original study population. For the FAVORIT case-cohort study, a subcohort was selected to include a 15% random sample of participants with nonmissing baseline measurements of serum creatinine, eGFR cr , cholesterol, and triglycerides, no missing follow-up, and stored serum and urine samples available (a key component of the case-cohort study for additional novel biomarker measurements); 3530 of the 4110 participants in the overall FAVORIT trial cohort met these criteria, 530 of whom were selected for the subcohort (28) (29) (30) . For the present analyses, we additionally excluded participants in the subcohort with missing serum measurements of cystatin C and B2M or key model covariates at baseline (N = 22). Weighted Cox proportional hazards regression analyses for adjudicated cardiovascular events included 306 participants with events (54 events that overlap with the subcohort), resulting in an analytic study sample of 760 participants. Analyses for all-cause mortality included 382 participants with events (68 events that overlap with the subcohort), resulting in an analytic sample of 822 participants. Analyses for dialysis-dependent kidney failure included 280 participants with events (52 events that overlap with the subcohort), resulting in an analytic sample of 736 participants.
Exposure assessment
Serum creatinine was previously measured in 2011 from frozen samples collected during the baseline study visit following a single thaw. Serum creatinine assays were performed at the United States Department of Agriculture Jean Mayer Human Nutrition Research Center on Aging at Tufts University using an alkaline picrate kinetic method on an Olympus AU 400e (Olympus America Inc, Center Valley, PA) instrument (coefficient of variation intra-assay 2.0%; interassay 4.0%), calibrated to an isotope dilution mass spectrometry traceable standard (8) . Serum cystatin C and B2M were measured at the Brigham and Women's Hospital in 2012 in previously frozen baseline EDTA-treated plasma samples using a Roche Cobas C6000 analyzer (Roche Diagnostics, Indianapolis, IN). Cystatin C assays were calibrated to an IFCC standard. Total imprecision of the B2M assay was 1.7% at 2.42 mg/L and 1.9% at 5.60 mg/L. Total imprecision of the cystatin C assay was 3.7% at 0.78 mg/L and 2.0% at 3.43 mg/L. Filtration markers were transformed to eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine (2009), cystatin C (2012), and B2M (2015) estimation equations (31) (32) (33) to allow comparisons across markers on the same scale (mL/min/ 1.73 m 2 ).
Outcome assessment
Outcomes included adjudicated cardiovascular events, all-cause mortality, and dialysis-dependent kidney failure. Adjudicated cardiovascular events included cases of cardiovascular death, myocardial infarction, resuscitated sudden death, and stroke that were centrally adjudicated and reviewed by the FAVORIT Clinical Endpoints Committee. Dialysis-dependent kidney failure was defined as the need for chronic dialysis as ascertained by local study staff.
Covariate assessment
Demographic, clinical, and transplant characteristics were assessed at the time of study enrollment. Smoking status was defined based on selfreport and categorized as current, former, or never smoking status. Transplant characteristics included donor type (living vs. deceased donor) and vintage (years since transplant). Baseline systolic and diastolic blood pressure was defined as the average of two measurements. Body mass index (BMI) was calculated as weight/height 2 (kg/m 2 ). Diabetes was defined as the use of insulin or oral hypoglycemic medications or based on self-report. Self-reported prevalent cardiovascular disease at baseline included prior myocardial infarction, coronary artery revascularization, stroke, carotid arterial revascularization, abdominal or thoracic aortic aneurysm repair, and/or lower extremity arterial revascularization or nontraumatic amputation above the ankle. Additional laboratory measurements included serum cholesterol measurements.
Statistical analyses
Baseline demographic and clinical characteristics are presented for the subcohort of 508 participants, overall, and by eGFR cys and eGFR B2M categories. We calculated Pearson correlation coefficients between eGFR cys , eGFR B2M , and eGFR cr within the subcohort. Associations of eGFR cys , eGFR B2M , and eGFR cr with adjudicated cardiovascular events, all-cause mortality, and dialysis-dependent kidney failure were first evaluated using Kaplan-Meier survival curves with log-rank tests in the subcohort (N = 508). We then used weighted Cox proportional hazards regression in the full analytic samples for each outcome to evaluate the association of eGFR cys , eGFR B2M , and eGFR cr with events to account for the weighted study design, similar to prior work in this case-cohort (28) (29) (30) 34) . Model adjustment included (1) adjustment for demographic and transplant characteristics (age, sex, race, country, randomized treatment assignment, donor type, graft vintage); (2) additional multivariable adjustment for baseline cardiovascular disease, diabetes, smoking status, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure, BMI, and natural log-transformed urinary albumin to creatinine ratio; and (3) additional adjustment for eGFR cr in models with eGFR cys or eGFR B2M as the primary predictor of interest. Exposures were modeled categorically and continuously in analyses. Statistical analyses were performed in Stata, Version 12.1 (StataCorp LP) and SAS Version 9.4 (SAS Institute Inc, Cary, NC).
Results
Baseline characteristics of the subcohort
In the subcohort (n = 508), mean age was 51.6 AE 9.2 years, 38.0% were female, 23.6% were of nonwhite race, and 68.5%, 13.5%, and 17.9% were recruited from centers in the United States, Canada, and Brazil, respectively (Table 1) ; characteristics of the subcohort are similar to those observed in the larger FAVORIT study cohort (8) . Participant characteristics across eGFR cys , eGFR B2M , and eGFR cr groups are presented in Tables 1, S1 , and S2, respectively. A strong correlation was observed between eGFR cys and eGFR B2M (Pearson correlation coefficient=0.87, p < 0.001); eGFR cys and eGFR B2M were more moderately correlated with eGFR cr (Pearson correlation coefficients of 0.61 and 0.55, respectively, both p < 0.001). Table S3 compares demographic characteristics and outcomes in the random subcohort to those who were not included in the subcohort. Serum creatinine was significantly higher and there was a trend toward a higher proportion of participants who developed kidney failure in participants selected in the subcohort.
Adjudicated cardiovascular events
Over a median follow-up of 3.6 years in the subcohort, 54 (10.6%) adjudicated cardiovascular events occurred. Kaplan-Meier survival analyses plots of the relationship between eGFR cys , eGFR B2M , or eGFR cr and cardiovascular outcomes in the subcohort are presented in Figure 1 .
In the case-cohort analysis in the full cardiovascular events analytic sample (N = 760) with weighted Cox proportional hazards regression, lower eGFR cys and lower eGFR B2M were each significantly associated with an increased risk of cardiovascular events after adjustment for demographic and transplant characteristics ( (Table 2 ).
All-cause mortality
Over a median follow-up of 3.8 years, 68 (13.3%) participants within the subcohort died. In Kaplan-Meier survival analyses, significant differences were observed across eGFR cys and eGFR B2M but not eGFR cr categories within the subcohort (Figure 2 ). In the case-cohort analysis in the full all-cause mortality analytic sample (N = 822) with weighted Cox proportional hazards regression, lower eGFR cys and lower eGFR B2M were each significantly associated with an increased all-cause mortality risk after accounting for demographic and transplant characteristics ( Dialysis-dependent kidney failure Over a median follow-up of 3.6 years, 52 (10.2%) of participants in the subcohort experienced dialysis-dependent kidney failure. In Kaplan-Meier survival analyses, significant differences were observed across eGFR cys , eGFR B2M , and eGFR cr groups curves within the subcohort (all log-rank p < 0.001; Figure 3 ). In case-cohort analyses in the full kidney failure analytic sample (N = 736) with weighted Cox proportional hazards regression, lower eGFR based on all three filtration markers was associated with increased risk of kidney failure when modeled categorically (all p-trend <0.001) or continuously (all p < 0.001, (Table 4) .
Discussion
Lower eGFR based on the low-molecular-weight serum proteins cystatin C and B2M is strongly associated with cardiovascular events, mortality, and dialysis-dependent kidney failure in stable kidney transplant recipients from the FAVORIT study. These associations persist following adjustment for several established risk factors and were independent of eGFR cr . As strong independent predictors of cardiovascular, mortality, and kidney events, these filtration markers are of interest as potential factors that could contribute to risk prediction in this population. Overall our findings are consistent with results for cystatin C and B2M observed in nontransplant populations (14) (15) (16) (17) (18) (19) (20) (21) and extend the current literature of the strong risk factor associations of these filtration markers with important outcomes into the kidney transplant population. Few studies have evaluated risk associated with cystatin C and B2M in kidney transplant recipients (22) (23) (24) (25) . In small studies (sample size from 79 to 129) higher cystatin C levels were associated with graft loss (24, 25) and higher serum B2M levels were also associated with eGFR cr decline at 1 and 2 years follow-up (22) . In the largest study to date, Astor and colleagues reported that higher serum B2M levels at discharge were associated with both mortality and graft loss and with associations of greater magnitude when compared to serum creatinine in a cohort of 2190 primary kidney transplant recipients from a single center in the United States (23). Our findings extend the current literature in kidney transplant recipients by confirming that cystatin C and B2M are strongly associated with mortality and dialysis-dependent kidney failure in a diverse cohort of stable kidney transplant recipients from the United States, Canada, and Brazil, in addition to our novel findings related to increased risk of cardiovascular events.
It is difficult to compare the magnitude of the risk associations that we observed for eGFR cys and eGFR B2M with those for eGFR cr . The HRs for eGFR cys and eGFR B2M with cardiovascular events, mortality, and dialysis-dependent kidney failure are larger than those observed for eGFR cr in the present case-cohort analysis as well as those observed in a previous study in the full FAVORIT cohort (8) . In the previous study, the HRs for eGFR cr with cardiovascular disease and all-cause mortality were modestly stronger than in this study and statistically significant, although current estimates fall within prior 95% CIs with substantial overlap. These differences may be related to the sampling design in the case-cohort study, which may reduce the relative efficiency of the eGFR cr analyses compared to the full cohort. A different reference group was also selected in the previous study (eGFR cr 60-75 mL/ min/1.73 m 2 ), whereas we combined the two highest categories of 60-75 and 75+ for more stable estimates due to our smaller size. Given the null findings in the 75+ compared to the reference group 60-75 mL/min/1.73 m 2 in the previous study, it is less likely that this difference explains the eGFR cr associations observed here. Our interpretation is that the risk associations of eGFR cys and eGFR B2M with these outcomes are likely as strong, and possibly stronger, than for eGFR cr . Risk associations of eGFR cys , eGFR B2M , and eGFR cr with important adverse outcomes reflect risk related both to GFR and to non-GFR determinants of the serum levels of the filtration markers. For creatinine, muscle mass is the main non-GFR determinant, and age, sex, and race are incorporated into eGFR cr as surrogates in populations where major deviations in muscle mass are not expected. Factors that reduce muscle mass, such as chronic illness and glucocorticosteroid use, may lead to overestimation of GFR and consequent attenuation of risk associations with eGFR cr .
The non-GFR determinants of cystatin C and B2M are not as well understood. Cystatin C is a 120 amino acid serine protease inhibitor that serves many biologic functions. In nontransplant populations, factors associated with non-GFR determinants of cystatin C include larger body size, inflammation, male sex, and smoking (35) (36) (37) (38) . Results from in vitro studies indicate that cystatin C is generated by immune cells and adipose tissue, consistent with variation in generation of cystatin C independent of GFR (39, 40) . As in the nontransplant population, obesity and inflammation may affect serum levels of cystatin C in kidney transplant recipients and contribute to increased risk of adverse outcomes independent of decreased GFR. In kidney transplant recipients, recent work suggests that multiple cardiovascular risk factors are associated with eGFR cys independent of measured GFR, including higher age, diabetes, smoking, cardiovascular disease, dialysis, higher BMI, higher serum triglycerides, higher urine protein, and higher hemoglobin A1c, representing a larger number of non-GFR determinants associated with cystatin C when compared to creatinine (41) . This suggests that the differential risk associations observed in our study may reflect risk related to non-GFR determinants of cystatin C rather than kidney function.
B2M is a 100-amino acid protein that is a component of class I major histocompatibility molecules and is present on the surface of nucleated cells. B2M is higher in some lymphoproliferative and plasma cell disorders and has been used as a biomarker in these conditions (42, 43) . Previous studies have investigated serum B2M in kidney transplant recipients and maintenance hemodialysis patients. In kidney transplant recipients, serum B2M has been studied as a marker of allograft rejection (23) and cytomegalovirus infection (44) , but results are confounded by its strong relationship to GFR. In patients treated with maintenance hemodialysis, higher serum B2M has been associated with increased all-cause and infectious mortality risk (45, 46) . While non-GFR determinants of B2M have not been evaluated in kidney transplant recipients, in maintenance hemodialysis patients factors associated with higher levels of predialysis serum B2M included lower age, black race, diabetes, lower BMI, longer dialysis duration, lower residual kidney function, and lower dialysis B2M clearance (45) . In nontransplant and nondialysis populations, factors most strongly associated with non-GFR determinants of B2M include higher urine protein, smoking, lower serum albumin, diabetes, and higher C-reactive protein, with weaker associations observed for lower age, male sex, nonblack race, and higher BMI (38) . It is possible that some of the mechanisms underlying these associations also contribute to the increased risk observed with B2M levels independent of GFR in kidney transplant recipients.
Our study has several limitations. Our study sample was drawn from a selected sample of stable kidney transplant recipients with decreased kidney function and elevated serum homocysteine and may not be representative of the general kidney transplant population. The casecohort design utilized a 15% random sample to estimate the exposure distribution in the overall study. Although demographic characteristics in the random subcohort are similar to those observed in previous analyses in the overall cohort, we did observe that serum creatinine was higher in participants selected in the subcohort compared to those who were not included in the subcohort from the overall population (Table S3 ) and we cannot rule out the impact of subcohort selection on the differences in eGFR cr with outcomes observed in the overall cohort, where eGFR cr was statistically associated with cardiovascular disease and all-cause mortality (8) . We also observed a nonsignificant increased incidence of dialysisdependent kidney failure in participants selected in the subcohort compared to those who were not included in the subcohort (Table S3) , which may impact the generalizability of the findings to the overall kidney transplant population. Cystatin C and B2M were measured once in previously frozen baseline serum samples. Serum levels may vary over time, but we anticipate that variability would be nondifferential with respect to outcome assessment and would likely bias our results towards the null. The B2M assay method performed at Brigham and Women's Hospital has not been directly compared to the method used at the University of Minnesota, where the CKD-EPI eGFR B2M equation was developed.
We did not assess all potential factors associated with non-GFR determinants of filtration markers, such as C-reactive protein, which contribute to the association of filtration markers with outcomes. Finally, eGFR cys and eGFR B2M equations were not developed in the kidney transplant population, which may lead to bias and imprecision in estimates based on different filtration markers; however, this effect is likely nondifferential with respect to outcome assessment, potentially biasing associations towards the null.
This study has a number of strengths. Our study sample was drawn from a multinational, well-characterized cohort of stable kidney transplant recipients with longterm follow-up for adjudicated cardiovascular events, allcause mortality, and dialysis-dependent kidney failure. The case-cohort study design is an efficient methodological approach for studying associations of novel factors with risk for multiple outcomes within a large existing cohort.
In conclusion, we found that the eGFR based on the low-molecular-weight serum protein filtration markers cystatin C and B2M are independent predictors of cardiovascular events, mortality, and dialysis-dependent kidney failure in stable kidney transplant recipients from the FAVORIT trial. Further work is needed to characterize non-GFR determinants of cystatin C and B2M and to evaluate the impact of low-molecular-weight serum protein filtration markers on risk prediction beyond creatinine in kidney transplant recipients.
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